Aegera Therapeutics Inc. and The Leukemia & Lymphoma Society (LLS) today jointly announced the execution of an agreement for $3.3 million (U.S.) to support an international Phase I/II clinical trial. The trial is for Aegera's AEG35156, a targeted therapy for blood cancer patients with follicular lymphoma (FL), small lymphocytic lymphoma and chronic lymphocytic leukemia (CLL)....
Read More...
[Source: Society News]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment